Dyne Therapeutics 

Yahoo Finance • 6 days ago

DYN Crosses Above Key Moving Average Level

In trading on Thursday, shares of Dyne Therapeutics Inc (Symbol: DYN) crossed above their 200 day moving average of $13.82, changing hands as high as $13.98 per share. Dyne Therapeutics Inc shares are currently trading up about 5.9% on th... Full story

Yahoo Finance • 28 days ago

Dyne Therapeutics to Present at Upcoming Investor Conferences

WALTHAM, Mass., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announ... Full story

Yahoo Finance • 30 days ago

Dyne Therapeutics stock rises after Raymond James upgrade to Strong Buy

Investing.com -- Dyne Therapeutics Inc (NASDAQ:DYN) stock jumped 4.1% after Raymond James analyst Martin Auster upgraded the company from Outperform to Strong Buy and raised the price target to $35.00 from $31.00. The upgrade reflects inc... Full story

Yahoo Finance • 30 days ago

Stocks Turn Mixed on Strength in the Magnificent Seven Megacaps

The S&P 500 Index ($SPX) (SPY) today is down by -0.15%, the Dow Jones Industrials Index ($DOWI) (DIA) is down by -0.49%, and the Nasdaq 100 Index ($IUXX) (QQQ) is up by +0.03%.  September E-mini S&P futures (ESU25) are down -0.13%, and Sep... Full story

Yahoo Finance • 30 days ago

Stocks Pressured by Rising Bond Yields

The S&P 500 Index ($SPX [https://www.barchart.com/futures/quotes/$SPX/overview]) (SPY [https://www.barchart.com/etfs-funds/quotes/SPY/overview]) today is down by -0.15%, the Dow Jones Industrials Index ($DOWI [https://www.barchart.com/futu... Full story

Yahoo Finance • last month

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN

NEW YORK, Aug. 17, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Dyne Therapeutics, Inc. (“Dyne” or the “Company”) (NASDAQ: DYN).  Such investors are advised to contact Danielle Peyton at newac... Full story

Yahoo Finance • last month

Sarepta Therapeutics’ SWOT analysis: stock faces challenges amid promising pipeline

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a biotechnology company specializing in RNA-targeted therapeutics for rare neuromuscular diseases, finds itself at a critical juncture. With a market capitalization of approximately $2 billion and... Full story

Yahoo Finance • 2 months ago

Avidity Biosciences stock soars on Novartis takeover approach report

Investing.com -- Avidity Biosciences (NASDAQ:RNA) stock surged 18% Wednesday after the Financial Times reported that Swiss pharmaceutical giant Novartis (NYSE:NVS) has approached the rare disease-focused biotech company about a potential t... Full story

Yahoo Finance • 2 months ago

Dyne Therapeutics stock rises after FDA grants breakthrough therapy status

Investing.com -- Dyne Therapeutics Inc (NASDAQ:DYN) stock rose 3.6% after the company announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to its DYNE-251 treatment for Duchenne muscular... Full story

Yahoo Finance • 2 months ago

Dyne Therapeutics Announces FDA Breakthrough Therapy Designation for DYNE-251 in Duchenne Muscular Dystrophy (DMD)

- Data from the DELIVER registrational expansion cohort is expected in late 2025, with a potential BLA submission for U.S. accelerated approval anticipated in early 2026 - WALTHAM, Mass., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeut... Full story

Yahoo Finance • 2 months ago

Can Dyne Deliver And Achieve Milestones In DMD And Myotonic Dystrophy Trials?

(RTTNews) - Dyne Therapeutics Inc. (DYN), a clinical-stage company developing treatments for genetically driven neuromuscular diseases, is advancing its programs in Myotonic Dystrophy and Duchenne Muscular Dystrophy, aiming for potential c... Full story

Yahoo Finance • 2 months ago

Dyne Therapeutics extends cash runway as it advances key drug programs

Investing.com -- Dyne Therapeutics, Inc. (NASDAQ:DYN) reported a second quarter loss that slightly missed analyst expectations as the clinical-stage biotech company continues to advance its neuromuscular disease therapies toward potential... Full story

Yahoo Finance • 2 months ago

Dyne Therapeutics GAAP EPS of -$0.97 misses by $0.01

* Dyne Therapeutics press release [https://seekingalpha.com/pr/20179912-dyne-therapeutics-reports-second-quarter-2025-financial-results-and-recent-business] (NASDAQ:DYN [https://seekingalpha.com/symbol/DYN]): Q2 GAAP EPS of -$0.97 misses... Full story

Yahoo Finance • 2 months ago

Dyne Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights

- Expected cash runway extended into Q3 2027, beyond multiple potential inflection points including Dyne’s first planned commercial launch in early 2027 - - Registrational Expansion Cohort of DELIVER Trial of DYNE-251 in DMD fully enrolle... Full story

Yahoo Finance • 2 months ago

Wednesday 7/16 Insider Buying Report: DYN, HELE

Bargain hunters are wise to pay careful attention to insider buying, because although there are many various reasons for an insider to sell a stock, presumably the only reason they would use their hard-earned dollars to make a purchase, is... Full story

Yahoo Finance • 2 months ago

Satellos Bioscience names new chief medical officer

* Satellos Bioscience (TSX:MSCL:CA [https://seekingalpha.com/symbol/MSCL:CA]) appointed [https://seekingalpha.com/pr/20167447-satellos-appoints-dr-wildon-farwell-as-chief-medical-officer] Wildon Farwell, M.D., MPH, as chief medical of... Full story

Yahoo Finance • 2 months ago

RBC Capital Maintains a Buy Rating on Dyne Therapeutics (DYN) With a $25 PT

Dyne Therapeutics, Inc. (NASDAQ:DYN) is one of the 13 Best Healthcare Stocks to Buy Under $10. In a report released on July 7, Luca Issi from RBC Capital maintained a Buy rating on Dyne Therapeutics, Inc. (NASDAQ:DYN) with a price target o... Full story

Yahoo Finance • 3 months ago

Dyne Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares

WALTHAM, Mass., July 02, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq:DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announc... Full story

Yahoo Finance • 3 months ago

Stocks Settled Mixed as Higher Bond Yields Weigh on Sentiment

The S&P 500 Index ($SPX [https://www.barchart.com/futures/quotes/$SPX/overview]) (SPY [https://www.barchart.com/etfs-funds/quotes/SPY/overview]) Tuesday closed down -0.11%, the Dow Jones Industrials Index ($DOWI [https://www.barchart.com/f... Full story

Yahoo Finance • 3 months ago

Stocks Pressured as Bond Yields Climb on Strong US Economic News

The S&P 500 Index ($SPX) (SPY) today is down -0.28%, the Dow Jones Industrials Index ($DOWI) (DIA) is up +0.51%, and the Nasdaq 100 Index ($IUXX) (QQQ) is down -0.80%.  September E-mini S&P futures (ESU25) are down -0.28%, and September E-... Full story